vimarsana.com

Latest Breaking News On - Alfred witjes - Page 1 : vimarsana.com

Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

SHANGHAI, Jan. 29, 2024 /PRNewswire/ Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering,

United statesLinda wuAlfred witjesAsieris pharmaceuticals stock codeAsieris pharmaceuticalsStock codeClinical oncology genitourinary cancers symposiumChief development officerClin oncolThailand business

Asieris to present a study protocol of APL-1202 in combination with BeiGene s tislelizumab as neoadjuvant therapy（NAC）for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting

/PRNewswire/ Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the.

United statesAlfred witjesAsieris pharmaceuticalsAmerican society of clinical oncologyNational medical products administration of chinaDrug administrationClinical oncologyDrug evaluationNational medical products administrationClin oncolNatl cancer inst

vimarsana © 2020. All Rights Reserved.